VRNA Verona Pharma ADS

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual

inhibitor of PDE3 and PDE4 for a broad COPD population


LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference (“ATS”) 2025. The posters are published on the ATS website and in the publication, American Journal of Respiratory and Critical Care Medicine.

Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years.

The ENHANCE posters highlight subgroup analyses of patients when used as monotherapy, in patients with COPD and comorbid cardiac disorders and, separately, in patients with COPD and comorbid type 2 diabetes. An analysis of Ohtuvayre’s effect on COPD exacerbations relative to lung function results will also be presented. Nonclinical posters describe a tissue distribution study in rat demonstrating lack of brain exposure, and a bleomycin model in rat demonstrating antifibrotic effects following inhaled ensifentrine dosing. In addition, the Company will have an exhibition booth, 2237, which will host presentations led by clinical experts.

Details of Verona’s posters are listed below and linked to the ATS website.

Poster P275: Presenter: Isaac Biney, MBChB, University of Tennessee Medical Center

Session: B52 – Hot Topics in COPD

Poster P283:  

Presenter: Matthew Moll, MD, Brigham and Women’s Hospital 

Session: B52 – Hot Topics in COPD

Poster P284:  

Presenter: Nirupama Putcha, MD, Johns Hopkins University 

Session: B52 – Hot Topics in COPD

Poster P285:  

Presenter: Michael Bradley Drummond, MD, University of North Carolina at Chapel Hill 

Session: B52 – Hot Topics in COPD

Poster P287:  

Presenter: George Washko, MD, Brigham & Women’s Hospital 

Session: B52 – Hot Topics in COPD

Poster P420:  

Presenter: Margot Macdonald-Berko, Verona Pharma 

Session: A71 Epithelial Dysfunction, inflammation and cigarette smoke: Drivers of COPD and CF Pathogenesis

Poster P891:  

Presenter: Trishul Siddharthan, MD, University of Miami 

Session: C49 – What’s New in COPD Phenotyping and Management

Poster P919:  

Presenter: Michael Lester, MD, Vanderbilt University Medical Center 

Session: B30 – Advanced Modalities to Uncover Pathophysiologic Features in COPD

Poster P924:  

Presenter: Margot Macdonald-Berko, Verona Pharma 

Session: D29 – From Bench to Bedside: Unraveling Pulmonary Fibrosis Through Cellular Communication and Molecular Pathways

Poster P943:  

Presenter: Auyon Ghosh, MD, Suny Upstate Medical University 

Session: B35 – ‘Omics and Outcomes: Translational Studies Across Lung Diseases

For further information please contact:

Verona Pharma plcTel:
Victoria Stewart, Senior Director of Investor Relations and Communications
Argot Partners

US Investor Enquiries
Tel:

Ten Bridge Communications

International / US Media Enquiries
Tel:

Wendy Ryan 
  

About Ohtuvayre (ensifentrine)

Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD.

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre and future poster presentations and academic publications pertaining to Ohtuvayre.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to the efficacy of Ohtuvayre compared to competing drugs; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on April 29, 2025, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law.



EN
06/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verona Pharma ADS

 PRESS RELEASE

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies...

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”),...

Verona Pharma: 3 directors

Three Directors at Verona Pharma sold after exercising options/sold 152,902 shares at between 71.602USD and 72.754USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...

 PRESS RELEASE

Verona Pharma Reports First Quarter 2025 Financial Results and Provide...

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the...

 PRESS RELEASE

Verona Pharma to Report First Quarter 2025 Financial Results and Provi...

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...

 PRESS RELEASE

Verona Pharma Announces Amended Strategic Financing with Oaktree and O...

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on impro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch